A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Eli Lilly said its recently approved weight loss treatment Zepbound is now available at pharmacies across the U.S. The drug serves as an alternative to rival obesity drugs such as Wegovy that are ...

Seemingly bad news can sometimes be really good news. I think a recent study for Eli Lilly's (LLY-2.28%) rival to Novo Nordisk's massively successful Ozempic and Wegovy provides a great case in point.

Eli Lilly on Wednesday said its obesity drug Zepbound led to more weight loss than its main rival, Novo Nordisk's Wegovy, in the first head-to-head clinical trial on the weekly injections. Watch ...

Eli Lilly & Co. Inc.'s stock (LLY) rose 2.3% Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk's Wegovy in a head-to-head study.

Eli Lilly said its Zepbound obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk's Wegovy in a head-to-head study of the two drugs ...

Eli Lilly (NYSE:LLY) said Wednesday its weight-loss drug Zepbound (tirzepatide) provided a 47% greater relative weight loss compared to Danish rival Novo Nordisk’s Wegovy (semaglutide) in the ...

Eli Lilly & Co. Inc.’s stock LLY rose 1.5% early Wednesday, after the company said its Zepbound weight-loss drug was more effective than rival Novo Nordisk’s Wegovy in a head-to-head study ...